Cefuroxime axetil for treatment of uncomplicated gonorrhea.

Antimicrobial Agents and Chemotherapy
A Gottlieb, J Mills

Abstract

Oral cefuroxime axetil (1 g) plus probenecid cured 29 of 30 urethral and 6 of 6 rectal gonococcal infections in men; alone the drug cured 22 of 23 urethral and 4 of 6 rectal infections. No toxicity was observed. Cefuroxime axetil alone is effective for urethral gonorrhea in males; rectal gonorrhea probably requires additional probenecid.

References

Jul 1, 1977·The Journal of Antimicrobial Chemotherapy·W O Godtfredsen
Jan 1, 1978·Chemotherapy·K H JonesL J Lees
May 1, 1976·Antimicrobial Agents and Chemotherapy·R D Foord
Oct 1, 1985·Sexually Transmitted Diseases·R C ReichmanJ Nitzkin
Oct 1, 1984·British Journal of Clinical Pharmacology·D K SommersH S Schoeman
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·S M HardingJ Ayrton
Feb 1, 1984·The Journal of Antimicrobial Chemotherapy·P E Williams, S M Harding

❮ Previous
Next ❯

Citations

Jul 1, 1995·International Journal of Antimicrobial Agents·J A García-RodríguezJ E García Sánchez
Mar 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lori M NewmanKimberly A Workowski
Dec 1, 1988·Genitourinary Medicine·R P DasD J Timmins
Jan 30, 1999·Sexually Transmitted Infections·F CrabbéG Dallabetta
Jun 1, 2000·Infectious Disease Clinics of North America·V H San Joaquin, T L Stull
Sep 1, 1988·Drug Intelligence & Clinical Pharmacy·M A Marx, W K Fant
Aug 31, 2021·The Journal of Antimicrobial Chemotherapy·Fiona Wing Yu LoJane S Hocking

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.